Ulcerative Colitis (UC)NCT07431983
Prospective Evaluation of the Carbon Footprint and Clinical Utility of IBUS Compared to Colonoscopy and Enterography in UC and CD
An observational study of Ulcerative Colitis (UC) and Crohns Disease, run by Asian Institute of Gastroenterology, India at 2 sites in India.
Trial summary
Healthcare contributes approximately 4.4% of global GHG emissions, with diagnostic imaging and endoscopic services being substantial contributors. Colonoscopy and cross-sectional imaging modalities, though indispensable, are associated with high carbon emissions due to electricity use, waste, sterilisation, and… Read more about this study
- Who is it for?
- Ages 18 to 80 years
- Conditions the study is for
- Ulcerative Colitis (UC), Crohns Disease
- How many people
- 200 participants
- Where
- 2 sitesIndia
- Study dates
- 1 Mar 2026to Dec 2026
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 80 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Duration: 12 months Sample Size: 100 UC patients (Colonoscopy + IBUS), 100 CD patients (CT/MRI enterography + IBUS), Total: 200 Patients
All consecutive patients undergoing endoscopy procedures with consent for procedures, during the study period will be included
Trial locations and contacts
2 sites in 1 country. Contact the study team or a site near you to ask about taking part.
India2 sites, 2 recruiting
- Recruiting
AIG Hospitals
Hyderabad, Telangana, 500032
Deepa Shukla, PhD, 995390017, deepa.shukla@aighospitals.com
Hardik Rughwani, MD, DM
- Recruiting
AIG Hospitals
Hyderabad, Telangana, 500032
Deepa Shukla, PhD, 995390017, deepa.shukla@aighospitals.com
About this study
Official title: Prospective Evaluation of the Carbon Footprint and Clinical Utility of Intestinal Bowel Ultrasound Compared to Colonoscopy and Enterography in Ulcerative Colitis and Crohn's Disease
Healthcare contributes approximately 4.4% of global GHG emissions, with diagnostic imaging and endoscopic services being substantial contributors. Colonoscopy and cross-sectional imaging modalities, though indispensable, are associated with high carbon emissions due to electricity use, waste, sterilisation, and transportation. IBUS, a non-invasive, real-time diagnostic modality, is increasingly validated for disease activity assessment in both UC and CD.
Read the detailed description
Healthcare contributes approximately 4.4% of global GHG emissions, with diagnostic imaging and endoscopic services being substantial contributors. Colonoscopy and cross-sectional imaging modalities, though indispensable, are associated with high carbon emissions due to electricity use, waste, sterilisation, and transportation. IBUS, a non-invasive, real-time diagnostic modality, is increasingly validated for disease activity assessment in both UC and CD. Its low energy footprint and portability make it a potential frontline tool for sustainable IBD follow-up. This study aims to quantify and compare the environmental impact and diagnostic value of IBUS versus conventional imaging strategies in real-world clinical care.
- Conditions
- Ulcerative Colitis (UC), Crohns Disease
- Medical subject headings
- Colitis, Ulcerative, Crohn Disease
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| Ulcerative colitis | carbon footprint and clinical usefulness of Intestinal Bowel Ultrasound (IBUS) with standard imaging colonoscopy in patients with Ulcerative Colitis Colonoscopy+ IBUS | |
| Crohns disease | carbon footprint and clinical usefulness of Intestinal Bowel Ultrasound (IBUS) with standard imaging CT/MRI enterography in patients with Crohn's Disease CT/MRI enterography+ IBUS |
What is being measured
The primary outcome is the main question the study is designed to answer.
The electricity consumed, water consumed, waste generated, and Greenhouse Gas (GHG) emissions will be analyzed
The waste generated will be stratified according to the methods of disposal as Direct landfill, Incineration, and landfill or Recyclable waste. The electricity consumed, water consumed, waste generated, and Greenhouse Gas (GHG) emissions will be analyzed. The unit of emissions will remain same kgCO2e and the total emissions will then be calculated.
Measured: 12 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted25 Feb 2026
- Study start1 Mar 2026
- Primary completionDec 2026 (estimated)
- Study completionDec 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (3)Papers the sponsor has linked to this study.
- Other trials for Ulcerative Colitis (UC)Studies of the same condition, open and under way.
- More trials run by Asian Institute of Gastroenterology, IndiaThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case only
- Time perspective
- Prospective
- Enrolment
- 200 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Asian Institute of Gastroenterology, India
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Mohan Ramchandani, Asian Institute of Gastroenterology, India
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07431983
- Sponsor's protocol ID
- IBUS1
- Status last verified
- Mar 2026
- First submitted
- 2 Dec 2025
- Last updated
- 12 May 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Publications
Expert Panel on Pediatric Imaging; Moore MM, Gee MS, Iyer RS, Chan SS, Ayers TD, Bardo DME, Chandra T, Cooper ML, Dotson JL, Gadepalli SK, Gill AE, Levin TL, Nadel HR, Schooler GR, Shet NS, Squires JH, Trout AT, Wall JJ, Rigsby CK. ACR Appropriateness Criteria(R) Crohn Disease-Child. J Am Coll Radiol. 2022 May;19(5S):S19-S36. doi: 10.1016/j.jacr.2022.02.020.
PubMed 35550801Namburar S, von Renteln D, Damianos J, Bradish L, Barrett J, Aguilera-Fish A, Cushman-Roisin B, Pohl H. Estimating the environmental impact of disposable endoscopic equipment and endoscopes. Gut. 2022 Jul;71(7):1326-1331. doi: 10.1136/gutjnl-2021-324729. Epub 2021 Dec 1.
PubMed 34853058Lenzen M, Malik A, Li M, Fry J, Weisz H, Pichler PP, Chaves LSM, Capon A, Pencheon D. The environmental footprint of health care: a global assessment. Lancet Planet Health. 2020 Jul;4(7):e271-e279. doi: 10.1016/S2542-5196(20)30121-2.
PubMed 32681898
Study at a glance
From the registry record, last updated by the sponsor on 12 May 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Prospective Evaluation of the Carbon Footprint and Clinical Utility of Intestinal Bowel Ultrasound Compared to Colonoscopy and Enterography in Ulcerative Colitis and Crohn's Disease
- ClinicalTrials.gov ID
- NCT07431983
- Acronym / sponsor ID
- IBUS1
- Conditions
- Ulcerative Colitis (UC), Crohns Disease
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 200 participants (estimated)
- Lead sponsor
- Asian Institute of Gastroenterology, IndiaUniversity, hospital or other
- Study start
- 1 Mar 2026 (actual)
- Primary completion
- Dec 2026 (estimated)
- Study completion
- Dec 2026 (estimated)
- First posted
- 25 Feb 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Healthcare contributes approximately 4.4% of global GHG emissions, with diagnostic imaging and endoscopic services being substantial contributors. Colonoscopy and cross-sectional imaging modalities, though indispensable, are associated with high carbon emissions due to electricity use, waste, sterilisation, and transportation. IBUS, a non-invasive, real-time diagnostic modality, is increasingly validated for disease activity assessment in both UC and CD.
Detailed description
Healthcare contributes approximately 4.4% of global GHG emissions, with diagnostic imaging and endoscopic services being substantial contributors. Colonoscopy and cross-sectional imaging modalities, though indispensable, are associated with high carbon emissions due to electricity use, waste, sterilisation, and transportation. IBUS, a non-invasive, real-time diagnostic modality, is increasingly validated for disease activity assessment in both UC and CD. Its low energy footprint and portability make it a potential frontline tool for sustainable IBD follow-up. This study aims to quantify and compare the environmental impact and diagnostic value of IBUS versus conventional imaging strategies in real-world clinical care.
Study design
- Observational model
- Case only
- Time perspective
- Prospective
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Ulcerative colitis | – | –carbon footprint and clinical usefulness of Intestinal Bowel Ultrasound (IBUS) with standard imaging colonoscopy in patients with Ulcerative Colitis Colonoscopy+ IBUS |
| Crohns disease | – | –carbon footprint and clinical usefulness of Intestinal Bowel Ultrasound (IBUS) with standard imaging CT/MRI enterography in patients with Crohn's Disease CT/MRI enterography+ IBUS |
Who may qualify
- Ages
- 18 to 80 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Duration: 12 months Sample Size: 100 UC patients (Colonoscopy + IBUS), 100 CD patients (CT/MRI enterography + IBUS), Total: 200 Patients
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
The electricity consumed, water consumed, waste generated, and Greenhouse Gas (GHG) emissions will be analyzed
Time frame: 12 months
The waste generated will be stratified according to the methods of disposal as Direct landfill, Incineration, and landfill or Recyclable waste. The electricity consumed, water consumed, waste generated, and Greenhouse Gas (GHG) emissions will be analyzed. The unit of emissions will remain same kgCO2e and the total emissions will then be calculated.
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 12 May 2026.
- Results publication: PubMed 35550801Expert Panel on Pediatric Imaging; Moore MM, Gee MS, Iyer RS, Chan SS, Ayers TD, Bardo DME, Chandra T, Cooper ML, Dotson JL, Gadepalli SK, Gill AE, Levin TL, Nadel HR, Schooler GR, Shet NS, Squires JH, Trout AT, Wall JJ, Rigsby CK. ACR Appropriateness Criteria(R) Crohn Disease-Child. J Am Coll Radiol. 2022 May;19(5S):S19-S36. doi: 10.1016/j.jacr.2022.02.020.
- Results publication: PubMed 34853058Namburar S, von Renteln D, Damianos J, Bradish L, Barrett J, Aguilera-Fish A, Cushman-Roisin B, Pohl H. Estimating the environmental impact of disposable endoscopic equipment and endoscopes. Gut. 2022 Jul;71(7):1326-1331. doi: 10.1136/gutjnl-2021-324729. Epub 2021 Dec 1.
- Results publication: PubMed 32681898Lenzen M, Malik A, Li M, Fry J, Weisz H, Pichler PP, Chaves LSM, Capon A, Pencheon D. The environmental footprint of health care: a global assessment. Lancet Planet Health. 2020 Jul;4(7):e271-e279. doi: 10.1016/S2542-5196(20)30121-2.
Related trials for Ulcerative Colitis (UC)
RecruitingObservational study
Ibd CAncer and seRious Infections in France (I-CARE 2)
IBD, Ulcerative Colitis
Not yet recruitingObservational study
Non-Invasive Biomarker Monitoring in UC on Biologics
Ulcerative Colitis
RecruitingPhase 2
LY4268989 in Adults With Moderately to Severely Active Ulcerative Colitis
Ulcerative Colitis (UC), Ulcerative Colitis, Active Moderate
RecruitingPhase 1/2
Safety, Dosage, and Microbiome Engraftment Study of MGT-006 for Ulcerative Colitis (ROOT Study)
Ulcerative Colitis (UC), Ulcerative Colitis, Active Moderate
RecruitingPhase 1/2
Study of XmAb942 in Healthy Participants and Participants With Ulcerative Colitis
Ulcerative Colitis (UC)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
2 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Ulcerative Colitis (UC) and Crohns Disease, run by Asian Institute of Gastroenterology, India at 2 sites in India.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 12 May 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 2 sites in India. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Dr.Hardik Rughwani (9426928600, dr.hardikr@aighospitals.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
The electricity consumed, water consumed, waste generated, and Greenhouse Gas (GHG) emissions will be analyzed (time frame: 12 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT07431983, which also lists 3 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 12 May 2026.